Dr. Reddy's Laboratories Launches Generic Version of Sapropterin Dihydrochloride Tablets for Oral Use in the US Market
5 October 2020 - - Indian drugmaker Dr. Reddy's Laboratories Ltd. (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) has launched a generic version of Sapropterin Dihydrochloride Tablets, for Oral Use, the company said.

Dr. Reddy's Sapropterin Dihydrochloride Tablets, 100 mg are available in bottle count sizes of 120.
Please see full prescribing information.

Dr. Reddy's is an integrated pharmaceutical company. The company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations.

Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets across the globe. The company's major markets include USA, India, Russia and CIS countries, and Europe.


Related Headlines